There are 302 resources available
67MO - Node-sparing modified short-course radiotherapy combined with CAPOX and tislelizumab in patients with MSS/pMMR locally advanced rectal cancer: A multicentre phase II trial (mRCAT)
Presenter: Zhangfa Song
Session: Mini Oral session 2
Resources:
Abstract
121MO - Anti-IL-8 (BMS-986253) in combination with nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with advanced melanoma: final analysis from the randomized part 2 of the phase 1/2 CA027-002 study
Presenter: Matteo Simonelli
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
176MO - ORCA-010 Oncolytic Therapy: Inducing Tumor-Specific Immune Responses and Activation of Tumor Microenvironment in Treatment-Naïve Prostate Cancer
Presenter: Tanja de Gruijl
Session: Mini Oral session 2
Resources:
Abstract
IO trials of EORTC
Presenter: JORDI REMON MASIP
Session: International IO trial activity by not-for-profit cooperative groups
Resources:
Slides
Webcast
Mature TLS formation to improve cancer sensitivity to immunotherapy
Presenter: Wolf-Hervé Fridman
Session: Secondary IO refractory cancers
Resources:
Slides
Webcast
IO trials of ETOP-IBCSG Partners Foundation
Presenter: Solange Peters
Session: International IO trial activity by not-for-profit cooperative groups
Resources:
Slides
Webcast
Modulating DNA damage response and cell death mechanisms to augment immune-mediated effects of radiotherapy
Presenter: Kevin Harrington
Session: Future directions for radio-immuno-oncology
Resources:
Slides
Webcast
What does a pragmatic trial mean?
Presenter: Roy S. Herbst
Session: International IO trial activity by not-for-profit cooperative groups
Resources:
Slides
Webcast
Collaboration between cooperative groups and industry
Presenter: Rolf A. Stahel
Session: International IO trial activity by not-for-profit cooperative groups
Resources:
Slides
Webcast
Strategies to overcome PD1 resistance in melanoma
Presenter: Anna Di Giacomo
Session: Secondary IO refractory cancers
Resources:
Slides
Webcast